Updated:
Livzon Mabpharm
Livzon Mabpharm is a monoclonal antibodies / biologics based in Zhuhai, founded 2010; the Altss profile covers its classification, headquarters, registration,...
Livzon Mabpharm
Livzon Mabpharm is a clinical-stage biotechnology company founded in 2010 in Zhuhai, China.
General information
Firm type
Monoclonal Antibodies / Biologics
Year founded
2010
Location
Region
Asia
Country
China
City
Zhuhai
Corporate office
Zhuhai, Guangdong, China
Additional offices
New York, United States
Frequently asked questions
Who runs investment decisions at Livzon Mabpharm?
Livzon Mabpharm is a subsidiary of Livzon Pharmaceutical Group, a publicly traded company. Its strategic direction is set by the parent group's leadership, though specific executives for the Mabpharm unit are not consistently disclosed in public filings (per Livzon Group's annual reports).
Is Livzon Mabpharm structured as a single family office or does it operate more like a venture firm?
Livzon Mabpharm is a corporate R&D and manufacturing subsidiary of Livzon Pharmaceutical Group, not a family office or venture firm. It operates within the parent company's pharmaceutical business model, focusing on biologic drug development and commercialization (public record).
What investment stages does Livzon Mabpharm typically target?
Livzon Mabpharm does not function as an investment firm; it is a biotechnology company. Its activities are product-stage oriented, from preclinical discovery through clinical trials and regulatory approval, primarily in China (per the firm's pipeline disclosures).
Which sectors does Livzon Mabpharm explicitly avoid?
Livzon Mabpharm focuses narrowly on monoclonal antibodies and biosimilars for oncology and autoimmune diseases, based on its publicly disclosed pipeline. No explicit avoidance policy is stated, but it has not publicly ventured into other therapeutic areas like vaccines or gene therapy (public record).
Where does the underlying wealth come from?
The firm is a subsidiary of Livzon Pharmaceutical Group, a publicly traded company on the Shenzhen Stock Exchange. Its funding originates from the parent group's pharmaceutical revenues, not from a disclosed family or individual fortune (public record).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: